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Abstract
Background: Ciglitazone belongs to the thiazolidinediones class of antidiabetic drug family and is a high-affinity ligand for
the Peroxisome Proliferator-Activated Receptor c (PPARc). Apart from its antidiabetic activity, this molecule shows
antineoplastic effectiveness in numerous cancer cell lines.
Methodology/Principal Findings: Using RT4 (derived from a well differentiated grade I papillary tumor) and T24 (derived
from an undifferentiated grade III carcinoma) bladder cancer cells, we investigated the potential of ciglitazone to induce
apoptotic cell death and characterized the molecular mechanisms involved. In RT4 cells, the drug induced G2/M cell cycle
arrest characterized by an overexpression of p53, p21
waf1/CIP1 and p27
Kip1 in concomitance with a decrease of cyclin B1. On
the contrary, in T24 cells, it triggered apoptosis via extrinsic and intrinsic pathways. Cell cycle arrest and induction of
apoptosis occurred at high concentrations through PPARc activation-independent pathways. We show that in vivo
treatment of nude mice by ciglitazone inhibits high grade bladder cancer xenograft development. We identified a novel
mechanism by which ciglitazone kills cancer cells. Ciglitazone up-regulated soluble and membrane-bound TRAIL and let
TRAIL-resistant T24 cells to respond to TRAIL through caspase activation, death receptor signalling pathway and Bid
cleavage. We provided evidence that TRAIL-induced apoptosis is partially driven by ciglitazone-mediated down-regulation
of c-FLIP and survivin protein levels through a proteasome-dependent degradation mechanism.
Conclusions/Significance: Therefore, ciglitazone could be clinically relevant as chemopreventive or therapeutic agent for
the treatment of TRAIL-refractory high grade urothelial cancers.
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Introduction
Urothelial carcinoma of the bladder accounts for ,5% of all
cancer deaths in humans. The majority of bladder tumors (75%)
are non muscle-invasive at diagnosis and after local surgical
therapy, have a high risk of recurrence and a propensity to
progress in grade or stage [1]. Muscle invasive tumors (25%) have
a poorer prognosis [2] since 50% of patients will relapse with
metastatic disease within 2 years of treatment. Despite the
advances with surgery and intravesical immuno- and chemother-
apy in the management of patients and although new chemother-
apeutic agents (tyrosine kinase inhibitors, anti-angiogenic
agents…) are used, no improvement in survival has been observed.
Thus, developing novel effective chemotherapeutic regimens with
fewer side effects are definitely needed to decrease the morbidity
and the mortality of urothelial carcinoma.
Thiazolidinediones (TZD), including rosiglitazone, troglitazone,
pioglitazone and ciglitazone are a class of insulin-sensitizing drugs.
Besides, rosiglitazone and pioglitazone are currently in clinical use
for the treatment of type II diabetes for million of patients. These
TZD are high-affinity chemically synthesized ligands of Peroxi-
some Proliferator-Activated Receptor c (PPARc) [3,4]. PPARc is
a ligand-activated transcription factor of the nuclear hormone
receptor superfamily. In addition to its known role in regulation of
metabolism and inflammation, PPARc has also been implicated in
carcinogenesis based on studies showing its ability to modulate
cellular differentiation, proliferation, and apoptosis. Apart from
their antidiabetic activity, TZD elicit growth inhibitory effects in
vitro on cancer cells of diverse tissue origins and in vivo [5]. Few
studies indicate that pioglitazone or troglitazone exhibited
antiproliferative or pro-apoptotic activities against bladder cancer
cell lines [6–9] and in rat urothelium [10]. Only one study
reported that ciglitazone exhibited inhibitory effects on cell
number in a series of cell lines modelling metastatic transitional
cell carcinoma of the bladder (TSU-Pr1, TSU-Pr1-B1 and TSU-
Pr1-B2) [6].
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mechanisms: the extrinsic death receptor-induced pathway
activated by proapoptotic receptor signals at the cellular surface,
and the intrinsic mitochondria-mediated pathway activated by
mitochondrial signals from within the cell [11]. The key mediators
of apoptosis are caspases, a family of cysteine proteases that cleave
a critical set of cellular proteins near specific aspartic acid residues.
Among potential effective anticancer treatments, TRAIL
(TNFa-related apoptosis inducing ligand) is a promising anti-
neoplastic agent because it induces apoptosis in cancer cells with
only negligible effect on normal cells [12]. TRAIL triggers caspase
cascade via the extrinsic apoptotic pathway through interaction
with TRAIL-responsive death receptors (DR), such as DR4 and
DR5, leading to the formation of the death-inducing signalling
complex (DISC), the recruitment and rapid activation of caspase
8. In type I cells, TRAIL-R-induced caspase-8 activation directly
results in downstream caspase activation and apoptosis, whereas in
type II cells caspase-8 activation is ineffective and the signal must
be amplified through caspase-8-cleavage of the pro-apoptotic Bid
protein and the activation of mitochondrial apoptotic pathway
[13] through caspase 9 activation. Both caspases 8 and 9 activate
the executioner caspase 3, which is the primary activator of
apoptotic DNA fragmentation and leads to cancer cell apoptosis
[14].
Survivin and cellular FLICE-inhibitory protein (c-FLIP) are
downstream and upstream anti-apoptotic regulators of the
apoptotic signaling cascade, respectively.
Like other inhibitors of apoptosis (IAP), survivin acts down-
stream of mitochondria to prevent processing or activation of
initiator caspase-9, leading to inhibition of the activity of the
effector caspases. However, the role of survivin is not limited to
apoptosis inhibition, but also involves the regulation of cell division
[15]. C-FLIP is the major protein that prevents caspase 8 from
activation by death receptors through binding to Fas-associated
death domain and caspase 8 at the DISC. Although multiple
splicing isoforms of c-FLIP mRNA have been described, only two
of them, c-FLIPS and c-FLIPL, have been significantly studied at
the protein level. Both proteins can be recruited to the death-
inducing signaling complex and inhibit death receptor-mediated
apoptosis [16]. Both c-FLIPL and c-FLIPS are quick turnover
proteins; thus, their levels are subject to regulation by ubiquitin/
proteasome-mediated degradation [17,18].
Results from preclinical studies with recombinant TRAIL have
demonstrated its significant anti-tumor activities, indicating the
potential of utilizing TRAIL as an anticancer agent [19]. Despite
this proapoptotic role of TRAIL in the transformed cells, many
cancer cells develop resistance towards TRAIL-induced apoptosis.
Thus, it has been reported that bladder cancer cell lines, such as
T24 and HT1376, are TRAIL-resistant [20]. Identification of
drugs or agents that can overcome TRAIL resistance and sensitize
cancer cells towards TRAIL-induced apoptosis is thus critically
important for targeting TRAIL-resistant cancer cells. The
combination of TRAIL with radiation and some chemotherapeu-
tic agents [21,22] have provided limited success, because this
combination also resulted in an increase in systemic toxicity.
The present study reported the effects of ciglitazone on RT4
(derived from a well differentiated grade I papillary tumor) and
T24 (derived from an undifferentiated grade III carcinoma)
bladder cancer cell lines. The choice of these particularly bladder
cancer cell lines is relevant since in RT4 cells, P53 is wild type and
the mesenchymal marker N-cadherin is not expressed whereas the
epithelial marker E-cadherin is detected. Inversely, in T24 cells,
P53 is mutated and E-cadherin is absent and replaced by N-
cadherin [23]. Thus, depending on differentiated state of the cells,
we showed that ciglitazone individual treatment induced G2/M
phase cell cycle arrest but triggered apoptosis only in T24 high
grade bladder cancer cells through PPARc activation-independent
mechanisms. In addition, for the first time to our knowledge, the
treatment of nude mice by ciglitazone significantly impairs the
growth of high grade bladder tumor xenografts confirming our in
vitro results. Most interestingly, the combination of ciglitazone and
TRAIL displayed that ciglitazone let TRAIL-refractory T24 cells
to respond to TRAIL. For the first time in bladder cancer cells, we
revealed that ciglitazone-mediated up-regulation of TRAIL and a
marked decrease of c-FLIP and survivin mediated in part through
a proteosomal degradation process contribute to ciglitazone-
induced cell death and to the sensitizing effect of this TZD on
TRAIL-induced apoptosis.
Results
Ciglitazone blocks RT4 (low grade) and T24 (high grade)
cells in G2/M phase but induces apoptosis only in T24
cells through caspase activation
To investigate the effect of ciglitazone on RT4 and T24 bladder
cancer cells apoptosis, cells were treated with varying concentra-
tions of drug (5–60 mM) for 24 h and assessed for propidium
iodide stained DNA content using flow cytometric analysis. As
shown in Figure 1A, in RT4 cells, the drug induced a dose-
dependent increase of cells in the G2/M phase of the cell cycle in
association with an increase of expression level of p53, p21
Cip1/
Waf1 and p27
Kip1 and a decline of cyclin B1 protein level
(Figure 1B). But there was no significant increase of the sub-G1
population compared to untreated control cells (Figure 1C)
indicating that a 24 h-ciglitazone treatment did not induce
apoptosis of these cells even at a high concentration of 60 mM
drug. Besides, ciglitazone did not induce cleavage of caspase 3 and
its substrate PARP (Figure 1D).
As observed for RT4 cells, there was a dose-dependent increase
of G2/M fraction of T24 cells (data not shown) but unlike RT4
cells, the analysis of nuclear DNA distribution in T24 cells showed
a dose-dependent increase of sub-G1 population with ,40% cell
death from 40 mM concentration (Figure 2A). To characterize the
cell death pathway triggered by ciglitazone, the cleavage of
caspases 9, 8, 3 was determined by western blotting analysis. From
a4 0 mM concentration of drug, a considerable enhanced
processing of both caspase 9 and caspase 8 to their active
fragments was detected (Figure 2B). Caspase 3 which represents
the classical downstream execution enzyme of caspase 8 and 9 was
cleaved into its active form (20/18 kDa). Activation of caspase 3
was confirmed by the cleavage of the pro-form PARP (116 kDa) to
the inactive form (85 kDa) (Figure 2B). As shown in Figure 2C,
while p53 and Bax expression levels were unchanged, Bcl-2 was
drastically decreased and Bid was truncated. These results
indicated that T24 cells could amplify the apoptotic signal through
the mitochondria and behave like type II cells after ciglitazone
exposure.
The caspase cascade activation is a key event for apoptotic
process. As expected, the incubation with caspase 8 (Z-IETD-
FMK) or 9 (Z-LEHD-FMK) specific inhibitors blocked caspases 8
or 9 processing (Figure 2D, left panel) and decreased the
ciglitazone-induced apoptosis as evidenced by a significant
decrease of sub-G1 population (Figure 2D, right panel) associated
with a less caspase 3 cleavage (Figure 2D, left panel). These data
indicate that RT4 and T24 cells did not have a similar response to
ciglitazone treatment. Indeed, ciglitazone-induced apoptosis was
restricted to T24 cells even though it blocked T24 and RT4 cells at
the G2/M phase of the cell cycle. In addition, the two main
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pathways, seem to be activated in T24 cells.
Ciglitazone did not act through PPARc transcriptional
activation
To determine whether PPARc transactivation was required for
ciglitazone-promoted cell cycle arrest or apoptosis, RT4 and T24
cells were treated for 24 h by 40 mM of drug alone or in
combination with 80 mM of GW9662, an irreversible potent
inhibitor of PPARc. The action of ciglitazone on G2/M cell cycle
arrest in RT4 cells was not inhibited (Figure 3A, left panel). As
expected, the increased expression level of p27
Kip1, observed with
ciglitazone, was not affected when GW9662 was associated with
the drug (Figure 3A, right panel). The impact of ciglitazone on
T24 cell death (Figure 3B, left panel) and caspase 3 cleavage
(Figure 3B, right panel) was not reversed in the presence of the
PPARc antagonist. Thus, GW9662 had no inhibitory effect but
yet it was effective since in T24 cells, it blocked the overexpression
of the A-FABP PPARc target upon ciglitazone treatment
(Figure 3C) as previously reported [24]. Taken together, this set
of experiments established that in T24 bladder cancer cells,
ciglitazone induced apoptosis through PPARc activation-indepen-
dent signalling pathways.
Ciglitazone up-regulates soluble and membrane-bound
TRAIL in T24 cells
We investigated whether ciglitazone can modulate the expres-
sion of TRAIL in T24 and RT4 cells. Upon 40 mM ciglitazone
exposure, we observed an increase of TRAIL ligand level in T24
whole cell extracts as assessed by western-blotting, an increase of
membrane-bound TRAIL as evidenced by flow cytometry analysis
with specific PE-conjugated TRAIL antibody, as well as an
increase of TRAIL level in T24 cell conditioned media determined
by ELISA (Figure 4A). On the other hand, ciglitazone, which did
not induce apoptosis in RT4 cells, did not raise TRAIL in whole
cell extracts as well as at the cell surface and in conditioned media
(Figure 4B). We thus believe that ciglitzone could cause apoptosis
of high grade T24 bladder cancer cells by increasing TRAIL
expression.
Ciglitazone did not affect DR4 and DR5 expression in T24
cells
In T24 cells, we have shown a caspase 8 cleavage and the
increase of TRAIL by ciglitazone. To analyse whether ciglitazone-
induced cell death is dependent on modification of death receptor
expression, cells were treated with 40 or 60 mM drug for 24 h. We
demonstrated that ciglitazone did not modify DR4 and DR5
expression level as assessed in whole cell lysates by western-blotting
(Figure 4C) as well as their cell surface expression as evidenced by
flow cytometry analysis with specific PE-conjugated antibodies
(Figure 4D). To investigate whether ciglitazone-triggered apoptosis
was a function of death receptor signalling amplification, DR4 and
DR5 stimulation was blocked by pre-incubation of cells with
blocking anti-DR4 or anti-DR5 antibodies before drug treatment.
The inactivation of both DR4 and DR5 significantly decreased the
ciglitazone-promoted apoptosis (Figure 4E). To validate the death
receptor blocking antibodies efficiency at the concentrations used,
we exposed TRAIL-sensitive RT4 cells to TRAIL as a positive
control (Figure 4E, insert). As expected, inactivating each of the
receptors completely inhibited TRAIL-induced apoptosis. These
data display that ciglitazone activates the extrinsic apoptotic
pathway through DR4 and DR5.
Ciglitazone inhibits bladder tumor xenograft
development in nude mice
To investigate the antitumor effect of ciglitazone in vivo
(Figure 5), T24 and RT4 cells as well were subcutaneously
injected in 6-week-old-female athymic nude mice. When palpable
Figure 1. Ciglitazone causes a G2/M cell cycle arrest in RT4 cells. Cells were treated for 24 h with or without ciglitazone at the indicated
concentrations. (A) Percentage of cells showing the cell cycle distribution. (C) Hypodiploid DNA content (sub-G1 peak). (B), (D) After treatment, cells
were harvested and total protein extracts were subjected to immunoblotting for detection of procaspase 3, PARP, p53, p21
Cip1/Waf1, p27
Kip1 and cyclin
B1. b-actin was used as an internal loading control. Data shown are representative of 3 independent experiments performed in triplicates.
doi:10.1371/journal.pone.0028354.g001
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(15 mg/kg) at the rate of one injection per week for three weeks.
Tumor volume was measured twice per week until the mice were
sacrificed. The tumor incidence was 100% in all animals. The
volume of the tumors in T24 cells-grafted mice did not increase in
ciglitazone-treated animals compared to vehicle-treated control
animals. There was a significant difference from the third injection
of ciglitazone (P,0.05) (Figure 5A, left panel). In RT4 cells-grafted
mice, tumor volume seemed to develop less than in control mice
upon ciglitazone treatment but this was not statistically significant
(Figure 5A, right panel). To determine whether the inhibition of
the tumor development by ciglitazone is due to inhibition of
proliferation, apoptosis, or both, we evaluated Ki67 expression
and caspase 3 activation on tumor tissue sections by immunohis-
tochemical analysis. The number of Ki67-positive cells was lower
in T24 and RT4 cells-xenografted tumor sections from ciglita-
zone-treated animals compared to tumor sections from untreated
animals. On the contrary, there was no detectable activated
caspase 3 in RT4 cells-xenografted tumor sections and a strong
activated caspase 3 staining in T24 cells-xenografted tumor
sections from ciglitazone treated animals compared to tumor
sections from untreated animals (Figure 5B). These results
Figure 2. Ciglitazone induces apoptosis in T24 cells. Cells were exposed for 24 h to vehicle or ciglitazone at the indicated concentrations. (A)
The percentage of cells showing the hypodiploid DNA content (sub-G1 peak) was evaluated by flow cytometry analysis. (B), (C) The cleavage of
caspases 9, 8, 3 and PARP as well as the expression of pro- and anti-apoptotic proteins were determined by western blotting analysis. (D, left) Cells
were preincubated 1 h with 50 mM caspase 8 (Z-IETD-FMK) or 9 (Z-LEHD-FMK) specific inhibitor before treatment with 40 mM ciglitazone for 12 h and
assessment of caspases 8, 9, 3 and Bid processing was analysed by western-blotting. b-actin was used as an internal loading control ; (D, right) After
indicated treatments, cells were stained with PI for DNA fragmentation analysis by flow cytometry. Data are means 6 SD of 3 independent
experiments performed in triplicates. *P,0.05, significant differences compared with untreated cells ; **P,0.05, significant differences compared
with ciglitazone-treated cells with the use of two-tailed unpaired Student’s t test.
doi:10.1371/journal.pone.0028354.g002
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reduction of tumor volume observed in ciglitazone-treated mice
(xenografted with T24 bladder cancer cells) requires the inhibition
of proliferation as well as the induction of apoptosis.
Ciglitazone and TRAIL combined treatment induces
synergistic apoptosis through death receptor signalling
pathway, caspase activation and Bid cleavage
T24 cells are known to be highly resistant to TRAIL after
exposure to increasing concentrations of exogenous soluble
recombinant human TRAIL ranging from 10 to 200 ng/ml
[25]. According to our results demonstrating that ciglitazone up-
regulates TRAIL expression, we postulated that ciglitazone kills
T24 cells by restoring their sensitivity to TRAIL-induced
apoptosis. To validate this hypothesis, cells were treated with
vehicle or 40 mM ciglitazone for 24 h or 50 ng/ml recombinant
TRAIL for the last 12 h alone or in combination. As previously
reported, we showed also that T24 cells were refractory to TRAIL-
induced apoptosis. More interestingly, there was a significant
increase of cell death in ciglitazone and TRAIL-cotreated cells
compared to ciglitazone alone-treated cells (Figure 6A, top). The
TRAIL-sensitizing action of ciglitazone resulted in pro-caspase 8
and 3 processing and PARP proteolysis but involved also the
mitochondria amplification loop as indicated by caspase 9 and Bid
cleavage (Figure 6A, bottom). In the presence of caspase 8 (Z-
IETD-FMK) or caspase 9 (Z-LEHD-FMK) specific inhibitors, we
observed an inhibition of either caspase 8 or caspase 9 processing
and the absence of Bid cleavage as well, in ciglitazone and TRAIL
cotreated cells (Figure 6B, bottom). This was associated with a
decrease of cell death in the presence of caspase inhibitors as
evidenced by a significant decrease of DNA fragmentation
(Figure 6B, top). To confirm the involvement of death receptor
activation, DR4 and DR5 stimulation was inhibited by pre-
incubation of cells with blocking anti-DR4 or anti-DR5 antibodies
before treatment (Figure 6C). Inactivating each of the receptors
upon TRAIL and ciglitazone cotreatment efficiently blocked cell
death confirming that apoptosis was mediated through specific
interactions between TRAIL and its receptors.
Ciglitazone down-regulates c-FLIP and survivin through a
proteasome-dependent degradation
We further investigated the effect of ciglitazone and the
association of ciglitazone with TRAIL on the expression of
apoptosis inhibitors such as survivin and c-FLIP known to be
involved in the regulation of both intrinsic and extrinsic apoptotic
pathways. As presented in Figure 6D, ciglitazone, as individual
treatment or in combination with TRAIL, reduced both c-FLIPS
and survivin protein levels to the same extent and dramatically
down-regulated c-FLIPL. On the contrary, TRAIL single
treatment did not affect considerably c-FLIP and survivin
protein levels. These findings indicate that down-regulation of c-
FLIP and survivin likely contributes to ciglitazone-triggered
apoptosis and to ciglitazone-mediated sensitization to TRAIL-
induced apoptosis.
Figure 3. Ciglitazone action is PPARc activation-independent. RT4 and T24 cells were treated for 24 h by 40 mM of ciglitazone alone or in
combination with 80 mM of GW9662, an irreversible potent inhibitor of PPARc. (A, left) Accumulation of RT4 cells in G2/M phase of the cell cycle was
analysed by flow cytometry analysis ; (A, right) After treatment, whole cell lysates were prepared and 20 mg of total protein extract were subjected to
immunoblotting for detection of p27
Kip1. (B, left) The percentage of cells showing hypodiploid DNA content (sub-G1 peak) was evaluated by flow
cytometry analysis ; (B, right) After treatment, whole cell lysates were prepared and 15 mg of total protein extract were subjected to immunoblotting
for detection of procaspase 3. (C) Assessment of the PPARc antagonist GW9662 efficiency on Adipocyte-Fatty Acid Binding Protein (A-FABP), a known
PPARc target in T24 cells by western-blotting analysis. b-actin was used as an internal loading control. Data are means 6 SD of 3 independent
experiments performed in triplicates. *P,0.05, significant differences compared with untreated cells with the use of two-tailed unpaired Student’s t
test.
doi:10.1371/journal.pone.0028354.g003
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PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28354Figure 4. Effect of ciglitazone on soluble and membrane-bound TRAIL and on DR4/DR5 receptors signaling pathway. RT4 and T24
cells were treated for 24 h with ciglitazone at 40 and/or 60 mM. In RT4 (A) and T24 (B) cells, whole cell lysates were assayed for TRAIL expression by
western-blotting analysis. b-actin was used as an internal loading control. Cells were stained with anti-TRAIL-PE and analysed by flow cytometry. After
40 mM ciglitazone treatment for 24 h, conditioned media were collected and the concentration of TRAIL was measured by ELISA. Data are means 6
SD of 2 independent experiments performed in quadruplicates. *P,0.05, significant differences compared with untreated cells with the use of two-
tailed unpaired Student’s t test. (C) Cellular proteins were isolated from T24 cells and subjected to immunoblotting for detection of DR4 and DR5. b-
actin was used as an internal loading control. (D) T24 cells were exposed to 40 mM ciglitazone for 12 h, stained with anti-DR4-PE or anti-DR5-PE and
analysed by flow cytometry. (E) T24 cells were preincubated with or without monoclonal antibodies blocking DR4 and DR5 receptors (5 mg/ml) for
1 h and stimulated for 12 h by 40 mM ciglitazone or 50 ng/ml TRAIL for RT4 cells (insert). The percentage of cells showing hypodiploid DNA content
(sub-G1 peak) was evaluated by flow cytometry analysis. Data are means 6 SD of 3 independent experiments performed in triplicates. *P,0.05,
significant differences compared with untreated cells ; **P,0.05, significant differences compared with ciglitazone-treated cells with the use of two-
tailed unpaired Student’s t test.
doi:10.1371/journal.pone.0028354.g004
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regulation of cell cycle control and apoptosis [26]. Several anti-
apoptotic proteins such as c-FLIP and survivin represent
prominent targets of the proteasome. To determine whether
the ciglitazone-induced down-regulation of such apoptosis
negative regulators is mediated through this process, we
investigated the effects of the proteasome inhibitor MG132.
MG132 restored the levels of survivin and c-FLIP (Figure 6E,
bottom) indicating that down-regulation of both apoptosis
inhibitors was proteasome dependent. As shown in the
Figure 6E (top) the sub-G1 cell population level in cotreated
cells was significantly decreased in the presence of MG132. Thus,
the recovery of c-FLIP and survivin, that significantly attenuated
ciglitazone and TRAIL combination-induced apoptosis, was
required but not sufficient to overcome cotreatment-promoted
apoptosis in T24 cells.
Figure 5. Antitumor activity of ciglitazone administered as monotherapy in athymic mice bearing T24 and RT4 bladder cancer
xenografts. Mice were inoculated subcutaneously with exponentially growing T24 and RT4 bladder cancer cells (5610
6 cells). When tumor size
reached 40 mm
3 in volume, mice were randomly divided into control and treated groups (n=10). Intraperitoneal injections of ciglitazone were
weekly administered at a dose of 15 mg/kg during three weeks. Control animals received only saline vehicle following an identical schedule. (A) The
growth tumor curves were determined by measuring the tumor volume. *P,0.05, significant differences compared with untreated animals with the
use of two-way ANOVA test (evaluation of the tumor volume development over time) ; **P,0.05, significant differences between control and treated
mice at each post-graft time with the use of two-tailed unpaired Student’s t test. (B) Immunohistochemical staining of representative paraffin-
embedded sections of tumors from untreated or ciglitazone-treated mice. Sections were fixed and stained for Ki-67 and active caspase 3. Each panel
is representative of 5 sections for each of ten tumors from control and ciglitazone-treated mice. Original magnification, 620.
doi:10.1371/journal.pone.0028354.g005
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downregulation. T24 cells were treated or not with 40 mM ciglitazone for 24 h or human recombinant TRAIL (50 ng/ml) for 12 h or cotreated with
ciglitazone and TRAIL (added here for the last 12 h). (A, top) The percentage of cells showing hypodiploid DNA content (sub-G1 peak) was evaluated
by flow cytometry analysis. Data are means 6 SD of 3 independent experiments performed in triplicates. *P,0.05, significant differences compared
with untreated cells; **P,0.05, significant differences compared with individual treatment-exposed cells with the use of two-tailed unpaired
Student’s t test; (A, bottom) Immunoblotting detection of caspases 8, 9 and 3, PARP and Bid. (B) Cells were preincubated 1 h with 50 mM caspase 8 (Z-
IETD-FMK) or 9 (Z-LEHD-FMK) specific inhibitor before indicated treatment; top, the percentage of cells showing hypodiploid DNA content was
evaluated by flow cytometry analysis; bottom, caspases 8, 9, 3 and Bid cleavage was assayed by western-blotting analysis. (C) Cells were preincubated
with or without monoclonal antibodies blocking DR4 and DR5 receptors for 1 h and stimulated as indicated. The percentage of cells showing
hypodiploid DNA content was evaluated by flow cytometry analysis. (D) Immunoblotting detection of c-FLIP and survivin from T24 whole cell lysates.
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The present report demonstrated that ciglitazone induced cell
growth inhibition through cell cycle course control or induction of
apoptosis according to the tumor grade of bladder cancer-derived
urothelial cells. Apoptotic effects occurred at high concentrations
(40–60 mM) independently of PPARc activation as already
reported in other cellular models [27]. Several potential PPARc-
activation independent mechanisms that may induce apoptosis
have been proposed. They include the generation of reactive
oxygen species [28], the induction of cellular acidosis [29], the
involvement of early growth response-1 and NSAID-activated-
gene 1 in colon cancer [30].
For the first time in malignant urothelial cells, we present
evidence that ciglitazone induced G2/M cell cycle arrest and
changes in cell cycle regulators. The major regulator of the G2 to
M transition is the MPF (M-phase promoting factor), which
comprises the catalytic subunit Cdc2 and the regulatory subunit
cyclin B1. Several observations suggest that p21
Cip1/Waf1 plays an
important role in G2/M checkpoint control. P21
Cip1/Waf1 inhibits
either Cdc2 kinase activity or prevent its activation by directly
binding to Cdc2, thereby blocking the interaction of cyclin B1-
Cdc2 complexes with their substrates [31]. Our results show that
in low grade papillary bladder tumor-derived RT4 cells,
ciglitazone led to the down-regulation of cyclin B1 protein level
and a marked increase in p21
Cip1/Waf1 and p27
Kip1 expression
associated with a raise of p53 protein level. P21 is normally
induced by p53. P53 has been identified as a direct target of
PPARc [32] and is a potent inhibitor of cellular proliferation. Its
expression leads to G1 phase arrest only [33] but some studies
reported that p53 hinders G2/M progression in the rat cell line
REF52 [34], in a human ovarian cancer cell line [35] and in skin
cells [36]. A recent study demonstrated that a prolonged exposure
of ciglitazone (72 h) increased p27
Kip1 protein level through both
induction of p27
Kip1 gene transcription as well as inhibition of
p27
Kip1 protein proteasome-mediated degradation [37]. No PPRE
or similar elements have been identified in the promoter. Besides,
in RT4 cells, p27
Kip1 up-regulation was not abolished by PPARc
specific antagonist arguing for the involvement of a PPARc
activation-independent mechanism. Ciglitazone could regulate
p27
Kip1 gene transcription through binding of Sp1 transcription
factor on Sp1 binding elements located in the promoter region as
described for 1,25 vitamin D3 in U937 cells [38].
Ciglitazone induced G2/M cell cycle arrest in both RT4 and
T24 cells but triggered apoptotic cell death only in T24 cells
through a PPARc-activation independent pathway. Very few
studies are available on the effect of ciglitazone in bladder cancer
cells. Chaffer et al. (2006) showed that this antidiabetic drug caused
a small decrease in cell number of TSU-Pr1/TSU-Pr1-B1/TSU-
Pr1-B2 cell lines after 24 h exposure, which subsided to a modest
10–15% inhibition over days 3 to 9. [39] reported that ciglitazone
induced cell death in HT-1376 and 5637 bladder cancer cell lines.
Here, we deepened and revealed the underlying mechanisms
involved in ciglitazone-induced apoptosis in high grade T24
bladder cancer cells. Our data support the involvement of both
intrinsic and extrinsic apoptotic signalling pathways as evidenced
by cleavage of caspases 9, 8 and 3 as well as the caspase substrate
PARP and the caspase processing blockage with the caspase 8 and
9 specific inhibitors. The cleavage of Bid protein in T24 cells
suggests that processing/activation of procaspase 8 drives the
caspase cascade with the requirement of the loop amplification
from the mitochondria. Most importantly, our study provides first
in vitro evidence of a novel mechanism by which ciglitazone
induces apoptosis through soluble and membrane-bound TRAIL
expression up-regulation leading to activation of DR4 and DR5
since their knockdown by specific blocking antibodies significantly
decreased ciglitazone-triggered apoptosis demonstrating their
critical role in this process. Only one study, carried out in animal
cells and more particularly in rat GH-secreting (GH3) cells,
revealed that ciglitazone-induced apoptosis was associated with an
increased expression of TRAIL assessed by western-blotting
analysis in whole cell extracts [40].
Malignant urothelial cells showed differential apoptotic suscep-
tibilities or resistance to TRAIL-induced apoptosis. We showed
that T24 cells were resistant to TRAIL as already reported
[20,25]. Oka et al. (2006) revealed that this protection from
TRAIL-induced apoptosis was related to a high expression of
constitutively active Akt. Here, we demonstrated that ciglitazone
sensitized cells to exogenous TRAIL. This result could have an
important impact for bladder cancer treatment. Indeed, TRAIL
could play a role in BCG-induced antitumor effects [41]. BCG
endovesical instillations are effective against bladder tumor
recurrence. According to some randomized controlled trials, only
BCG can curb progression. It has been postulated that BCG
stimulates the immune system by activating macrophages, T
lymphocytes, B lymphocytes, thus augmenting the host response to
tumor surveillance [42]. Functional TRAIL has been detected in
the urine of patients undergoing BCG therapy and increased urine
levels in those patients who responded to BCG immunotherapy
compared with non responders [41]. Thus, ciglitazone could
improve and potentiate BCG therapy in responders and sensitize
to BCG therapy in non responders.
The underlying mechanisms explaining how thiazolidinediones
sensitize cells to TRAIL-induced cell death remain poorly
understood but could involve the down-regulation of inhibitors
of apoptosis proteins [43], the ROS-mediated up-regulation of
DR5 [36] or the caspases 3 and 8-mediated b-catenin cleavage
[44]. It has been documented that some TZD decrease c-FLIP
[17] or survivin expression [45]. Interestingly, the present findings
propose that a down-regulation of c-FLIP was associated with
apoptosis induced by ciglitazone combined with TRAIL and the
reduction in survivin level could be partly responsible for the
action of ciglitazone on the TRAIL-promoted apoptosis in T24
cells. Survivin is expressed at high levels in many tumors and has
been described as a prognostic marker for bladder cancer
progression [46]. Survivin inhibits mitochondrial apoptosis but is
able to block TRAIL-induced cell death. This can be explained by
cross-links between extrinsic and intrinsic death pathways through
the Bid protein cleavage as detected upon ciglitazone treatment in
T24 cells. Survivin is a bifunctional protein. In addition to act as
an apoptosis inhibitor, survivin is a key regulator of mitosis and is
involved in G2/M transition. Besides, siRNA mediated down-
regulation of survivin in bladder cancer cell lines, such as RT4 and
T24, was associated with a specific G2/M arrest [47,48]. Now, we
showed that ciglitazone increased the fraction of RT4 and T24
(E) Cells were pretreated with 25 mM proteasome inhibitor MG132 for 30 min and stimulated with 40 mM ciglitazone for 12 h ; top, the percentage of
cells showing hypodiploid DNA content was evaluated by flow cytometry analysis ; bottom, immunoblotting detection of c-FLIP and survivin. b-actin
was used as an internal loading control. (B, C, E) Data are means 6 SD of 2 independent experiments performed in triplicates. *P,0.05, significant
differences compared with untreated cells ; **, P,0.05, significant differences compared with ciglitazone and TRAIL cotreated cells with the use of
two-tailed unpaired Student’s t test.
doi:10.1371/journal.pone.0028354.g006
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cyclin B1 is responsible for regulating survivin through phosphor-
ylation of Thr34 [49]. Thus, we could hypothesize that ciglitazone
led to the survivin down-regulation by acting on CDK1/cyclin B1
complex. The decrease of cyclin B1 associated with the RT4 and
T24 cells accumulation in G2/M phase of the cell cycle could
prevent the phosphorylation and accumulation of survivin,
removing a viability checkpoint through which it leads to apoptosis
in the case of T24 cells. Further experiments are needed to clarify
this point.
Several mechanisms explain TZD-mediated down-regulation of
downstream (survivin) and upstream (c-FLIP) anti-apoptotic
regulators of the apoptotic signalling cascade namely, ubiquitina-
tion and proteasome-dependent degradation with or without
transcriptional events [43,50]. Here, despite the recovery of
survivin and c-FLIP protein level after MG132 pretreatment, T24
cells did not completely rescue from cell death. The down-
regulation of both proteins is mediated partially through
proteasomal degradation because in the presence of MG132, the
protein levels did not reach those of untreated cells and this was
not sufficient to prevent ciglitazone-induced apoptosis. Further
investigations are needed to better understand the molecular
mechanisms involved in this process.
We have evaluated the potential anti-urothelial cancer activity
of ciglitazone in a mouse model of bladder cancer xenografts.
Importantly, our results showed that ciglitazone significantly
reduced the development of bladder tumors in mice xenografted
with high grade T24 cells but not in mice xenografted with low
grade RT4 cells. In addition, ciglitazone did not appear to induce
toxicity since the body weight and overall appearance of mice
given the drug were not different from those of controls (data not
shown). These data demonstrate that ciglitazone has a strong anti-
urothelial cancer activity in vivo. The immunohistochemical
analysis of caspase 3 activation suggests that in vivo ciglitazone
effects are cytotoxic and correlated with the induction of apoptosis.
So, to observe a significant reduction of bladder tumor
development, both inhibition of proliferation and induction of
apoptosis are needed.
Collectively, this work has identified a novel pathway for the
antitumor properties of ciglitazone in human bladder cancer cells.
We demonstrate for the first time that ciglitazone is able to reduce
bladder cancer development in an in vivo model. According to our
study, it is needed to elucidate in bladder cancer the distinct
PPARc-independent mechanisms of ciglitazone action prior to
clinical exploration. Furthermore, animal studies are warranted in
combination of ciglitazone and TRAIL to strengthen our in vitro
results.
We suggest that endovesical instillations of ciglitazone could be
used as individual treatment or in combination with TRAIL or
BCG therapy. This could be a potential efficient treatment tool for
bladder cancer.
Materials and Methods
Reagents
The PPARc agonist Ciglitazone and the PPARc antagonist
GW9662 were provided from Cayman Chemical. Soluble
recombinant TRAIL, proteasome inhibitor MG132, caspase 9
(Z-LEHD-FMK) specific inhibitor and propidium iodide (PI) were
purchased from Sigma. Caspase 8 (Z-IETD-FMK) inhibitor was
from Bachem (Heidelberg, Germany). The final concentration of
organic solvent (dimethylsulfoxide) was less than 0.1% which had
no effect on cell viability. DR4 and DR5 blocking antibodies were
from Alexis Biochemicals (Lausanne, Switzerland).
Cell lines, culture conditions, and treatment
The human bladder tumor cell lines RT4 and T24 were
obtained from ATCC. Cells were maintained in Mc COY’s 5a
medium supplemented with 10% fetal calf serum (FCS) (Invitro-
gen, Cergy Pontoise, France), 1% antibiotic antimycotic mixture
(10 mg/ml streptomycin, 10 000 units/ml penicillin, 25 mg/ml
amphotericin B), 2 mM glutamine and 15 mM Hepes (Sigma) at
37uC in a humidified 5% CO2, 95% O2 air incubator. Cells were
tested for the absence of mycoplasma before the beginning of
experiments. RT4 cells (4.2610
4 cells/cm
2) and T24 cells
(5.2610
3 cells/cm
2) were plated in 12-well plates for flow
cytometry analysis and in 6-well plates for protein extraction
and cultured in 5% FCS culture medium. After 24 h attachment,
cells were washed with serum-free culture medium and then
treated either with vehicle or with ciglitazone (5 to 60 mM) for
24 h or with TRAIL (20, 50, 100 ng/ml) for 12 h, alone or in
combination for 24 h in a serum-free culture medium. In that
case, TRAIL was added the last 12 h in the culture medium.
DNA fragmentation and cell cycle analyses
The distribution of cells in the sub-G1, G0/G1, S and G2/M
cell cycle phases was determined by flow cytometry. After
ciglitazone treatment, RT4 and T24 cells were detached with
trypsin/EDTA, washed in phosphate-buffered saline (PBS) and
centrifuged at 1 200 rpm for 10 min. Total population of cells,
including floating and adherent cells, was fixed overnight at 4uC
by cold absolute ethanol. After fixation followed by washes with
PBS/5 mM EDTA, cells were stained with 1 mg/ml propidium
iodide in 50 ml PBS/5 mM EDTA complemented with 1 mg/ml
RNAse A DNAse-free (Sigma) and incubated at room temperature
for 15 min. The DNA content was analysed by flow cytometry
using an excitation wavelength set at 488 nm and emission at
610 nm (FC 500, Beckman Coulter). Twenty thousand events
were analysed per sample and apoptosis was determined from the
Sub-G1 DNA content with CXP software (Beckman Coulter). The
percentages of nuclei in the G0/G1, S, G2/M phases of the cell
cycle were quantified using Multicycle analysis software (Beckman
Coulter). Gating was set to exclude cell debris, doublets, and
clumps.
Western blotting
After ciglitazone treatment, cells were washed with cold PBS and
scraped in 120 ml of lysis buffer RIPA (50 mM Tris-HCl pH 7.4,
150 mM NaCl, 1 mM EDTA, 1% Nonidet P40, 0.5% sodium
desoxycholate) supplemented with protease inhibitors (Roche,
Meylan, France). Then, cell lysates were sonicated and centrifuged
at 10 000 rpm for 10 min at 4uC. Protein concentration was
estimated using the Bio-Rad protein assay (Bio-Rad, Marnes-la-
Coquette,France).Protein extracts(20 mgforRT4cellsor15 mg for
T24 cells) were solved in Laemmli buffer (Bio-Rad) and separated
by a 7.5–15% SDS-PAGE. Proteins were transferred onto PVDF
membranes (GE Healthcare, Buckinghamshire, UK) and non
specific binding was blocked in TBS-Tween 20 buffer (0.5 mM
Tris-HCl, 45 mM NaCl, 0.05% Tween 20, pH 7.4) containing 5%
nonfat milk. Membranes were incubated for 1 h with the following
appropriate primary antibodies: mouse monoclonal anti-caspase 8
(clone 3-1-9, 1:1 000), anti-p21
Cip1/Waf1 (6B6, 1:500), anti-p27
kip1
(G173-524, 1:500), anti-p53 (DO-1, 1:500), anti-cyclin D1 (G124-
326, 1:1 000) and anti-PARP (4C10-5, 1:1 000) were obtained from
BD Pharmingen. Anti-mouse A-FABP (#AF1443, 1:1 000) was
from R&D Systems (Abingdon, UK). Mouse monoclonal cyclin B1
(1:1 000) was kindly gifted by Dr. Marchini (DKFZ, Heidelberg).
Rabbit polyclonal anti-caspase 9 (1:1 000), mouse monoclonal anti-
survivin (1:500) and mouse monoclonal Bid (1:500) were from Cell
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Stressgen (Victoria, Canada) and mouse monoclonal anti-c-FLIP
(NF6, 1:500) was from Alexis Biochemicals. Rabbit polyclonal anti-
DR4 (1:1 000), anti-DR5 (1:1 000) and anti-TRAIL (1:500) were
purchased from Chemicon International Inc. Protein blots were
probed with mouse monoclonal anti-b-actin (AC-15, Sigma) as
controls for protein loading. Bound primary antibodies were
detected using HRP-conjugated secondary antibodies: anti-rabbit
IgG (1:10 000) or anti-mouse IgG (1:10 000) provided from BD
Pharmingen. Proteins were visualized by using enhanced chemilu-
minescence detection method (GE Healthcare) followed by film
exposure (Hyperfilm ECL, GE Healthcare).
Assessment of cell surface DR4, DR5 and TRAIL
expression
Cells were treated with ciglitazone alone or in combination with
TRAIL as described above. They were detached with 5 mM
EDTA and centrifuged at 1 200 rpm for 10 min. Cells (1.10
6)
were resuspended in 50 mL of PBS and stained with 10 mLo f
phycoerythrin (PE)-conjugated mouse monoclonal anti-human
DR4 (clone B-N36), DR5 (clone B-K29) or TRAIL (clone B-S23)
provided by Diaclone (Besanc ¸on, France), for 30 min at 4uC in the
dark. Cells were then washed twice in 1% BSA-PBS and
resuspended in 50 mL of PBS. Flow cytometry analyses were
performed at a 580 nm wavelength. PE-conjugated mouse IgG1
was used as an isotype control.
Determination of TRAIL production
RT4 and T24 cells were seeded in triplicates in 6-well plates and
cultured in Mc COY’s 5a medium with 5% FCS for 24 h. The
following day, the cells were stimulated in serum-free medium with
40 mM ciglitazone for 24 h. Supernatants were collected and
TRAIL was quantified by enzyme-linked-immunosorbent assay
(Diaclone).
Tumor xenograft model
Five to eight-week-old female nu/nu nude mice were maintained
according to European Union guidelines for use of laboratory
animals. In vivo experiments were performed in compliance with
the French guidelines for experimental animal studies. Experi-
mental protocols were approved by the Departmental Direction of
the Veterinary Division of the Doubs, France (authorization
certificate Nu25-27/Approval ID: B 25-056-7). Exponentially
growing human bladder cancer cell lines RT4 and T24 were
subcutaneously injected into the right flank of female nude mice as
follows: 5610
6 cells in 50 mL PBS with 25% decomplemented
FCS for both cell lines but with 50 mL Matrigel (BD Biosciences)
for T24 cells. Animals were examined twice a week for tumor
development. When tumor size reached 40 mm
3 in volume, mice
were randomly divided into control and treated groups containing
ten mice each. Intraperitoneal injections of ciglitazone were
weekly administered at a dose of 15 mg/kg during three weeks.
Control animals received only saline vehicle following an identical
schedule. Tumor size was monitored twice a week by measuring
length and width with a calliper. Tumor volume was estimated
using the following formula: volume=width
26length6K. Mice
were sacrificed one week after the third injection and tumors were
removed.
Immunohistochemistry
Vehicle- and ciglitazone-treated tumors were collected, fixed in
4% formalin and paraffin-embedded. Then, blocks were cut
serially at 5 mm thick, deparaffinized in toluene, rehydrated in
graded ethanol. Antigen retrieval was achieved by micro-wave
treatment in 0.5 M Tris-buffered saline (pH 6.0) at 750 W for
30 minutes. Sections were then incubated with primary antibodies
at room temperature using an automated immunohistochemical
processor (Techmate 500 Plus, DakoCytomation, Trappes,
France) according to the manufacturer’s instructions. The
biotinylated primary antibody anti-Ki-67 (DakoCytomation,
MIB-1, 1:150) was used for evaluation of proliferating cells.
Activated caspase 3 was detected with Apoptosis marker:
SignalStain cleaved Caspase 3 (Asp175) IHC Detection kit (Cell
Signaling). Slides were then treated with alkaline phosphatase-
conjugated avidin. Finally, alkaline phosphatase activity was
revealed by NBT-BCIP. Sections were counterstained with Harris’
hematoxylin, dehydrated through alcohol and mounted using a
standard procedure. Negative controls were obtained by omitting
the first antibody. Slides were then examined and pictures were
taken using Zeiss Axioskop 40 photomicroscope.
Statistical analyses
For in vitro experiments, two-tailed unpaired Student’s t test was
used to examine the significant differences between groups. Data
are expressed as mean 6 SD of three independent experiments or
as specified for each figure. The in vivo therapeutic efficacy of
ciglitazone was assessed by evaluating the tumor volume
development over time with two-way ANOVA test. Differences
between control and treated mice at each post-graft time were
determined by Student’s t test. Values with P,0.05 were
considered significant.
Acknowledgments
We thank Sylviane Coumes-Marquet and Claude Collard for helpful
advice for immunohistochemistry, Virginie Mougey for flow cytometry
analysis and Franck Monnien for statistics.
Author Contributions
Conceived and designed the experiments: IL SF. Performed the
experiments: M-LP SF IL. Analyzed the data: IL SF M-LP. Wrote the
paper: IL SF M-LP HB.
References
1. Epstein JI, Amin MB, Reuter VR, Mostofi FK (1998) The World Health
Organization/International Society of Urological Pathology consensus classifi-
cation of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder
Consensus Conference Committee. Am J Surg Pathol 22: 1435–1448.
2. Lee R, Droller MJ (2000) The natural history of bladder cancer. Implications for
therapy. Urol Clin North Am 27: 1–13, vii.
3. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, et al.
(1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome
proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:
12953–12956.
4. Day C (1999) Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med
16: 179–192.
5. Rumi MA, Ishihara S, Kazumori H, Kadowaki Y, Kinoshita Y (2004) Can
PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anti-Canc
Agents 4: 465–477.
6. Chaffer CL, Thomas DM, Thompson EW, Williams ED (2006) PPARgamma-
independent induction of growth arrest and apoptosis in prostate and bladder
carcinoma. BMC Cancer 6: 53.
7. Guan Y, Zhang Y, Davis L, Breyer MD (1997) Expression of peroxisome
proliferator-activated receptors in urinary tract of rabbits and humans.
Am J Physiol 273: F1013–1022.
8. Nakashiro KI, Hayashi Y, Kita A, Tamatani T, Chlenski A, et al. (2001) Role of
peroxisome proliferator-activated receptor gamma and its ligands in non-
neoplastic and neoplastic human urothelial cells. Am J Pathol 159: 591–597.
Ciglitazone Induces Bladder Tumor Cells Apoptosis
PLoS ONE | www.plosone.org 11 December 2011 | Volume 6 | Issue 12 | e283549. Yoshimura R, Matsuyama M, Hase T, Tsuchida K, Kuratsukuri K, et al. (2003)
The effect of peroxisome proliferator-activated receptor-gamma ligand on
urological cancer cells. Int J Mol Med 12: 861–865.
10. Suzuki S, Arnold LL, Pennington KL, Kakiuchi-Kiyota S, Wei M, et al. (2010)
Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma
agonist, on the urine and urothelium of the rat. Toxicol Sci 113: 349–357.
11. Lavrik IN, Golks A, Krammer PH (2005) Caspases: pharmacological
manipulation of cell death. J Clin Invest 115: 2665–2672.
12. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, et al. (1999)
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand
in vivo. Nat Med 5: 157–163.
13. Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that
mediate cell death. Nat Rev Mol Cell Biol 9: 47–59.
14. Wolf BB, Schuler M, Echeverri F, Green DR (1999) Caspase-3 is the primary
activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/
inhibitor of caspase-activated DNase inactivation. J Biol Chem 274:
30651–30656.
15. Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008) Survivin: key regulator of
mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res
14: 5000–5005.
16. Yu JW, Shi Y (2008) FLIP and the death effector domain family. Oncogene 27:
6216–6227.
17. Kim Y, Suh N, Sporn M, Reed JC (2002) An inducible pathway for degradation
of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem
277: 22320–22329.
18. Poukkula M, Kaunisto A, Hietakangas V, Denessiouk K, Katajamaki T, et al.
(2005) Rapid turnover of c-FLIPshort is determined by its unique C-terminal
tail. J Biol Chem 280: 27345–27355.
19. Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y (1999) Selectivity of
TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to
non-toxic cancer therapeutics (review). Int J Oncol 15: 793–802.
20. Steele LP, Georgopoulos NT, Southgate J, Selby PJ, Trejdosiewicz LK (2006)
Differential susceptibility to TRAIL of normal versus malignant human
urothelial cells. Cell Death Differ 13: 1564–1576.
21. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, et al. (2000)
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and
ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 97:
1754–1759.
22. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S (1999)
Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer
Res 59: 734–741.
23. Lascombe I, Clairotte A, Fauconnet S, Bernardini S, Wallerand H, et al. (2006)
N-cadherin as a novel prognostic marker of progression in superficial urothelial
tumors. Clin Cancer Res 12: 2780–2787.
24. Boiteux G, Lascombe I, Roche E, Plissonnier ML, Clairotte A, et al. (2009) A-
FABP, a candidate progression marker of human transitional cell carcinoma of
the bladder, is differentially regulated by PPAR in urothelial cancer cells.
Int J Cancer 124: 1820–1828.
25. Oka N, Tanimoto S, Taue R, Nakatsuji H, Kishimoto T, et al. (2006) Role of
phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis
induced by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci
97: 1093–1098.
26. Jesenberger V, Jentsch S (2002) Deadly encounter: ubiquitin meets apoptosis.
Nat Rev Mol Cell Biol 3: 112–121.
27. Wei S, Yang J, Lee SL, Kulp SK, Chen CS (2009) PPARgamma-independent
antitumor effects of thiazolidinediones. Cancer Lett 276: 119–124.
28. Perez-Ortiz JM, Tranque P, Vaquero CF, Domingo B, Molina F, et al. (2004)
Glitazones differentially regulate primary astrocyte and glioma cell survival.
Involvement of reactive oxygen species and peroxisome proliferator-activated
receptor-gamma. J Biol Chem 279: 8976–8985.
29. Turturro F, Friday E, Fowler R, Surie D, Welbourne T (2004) Troglitazone acts
on cellular pH and DNA synthesis through a peroxisome proliferator-activated
receptor gamma-independent mechanism in breast cancer-derived cell lines.
Clin Cancer Res 10: 7022–7030.
30. Chintharlapalli S, Papineni S, Baek SJ, Liu S, Safe S (2005) 1,1-Bis(39-indolyl)-1-
(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor
gamma agonists but decrease HCT-116 colon cancer cell survival through
receptor-independent activation of early growth response-1 and nonsteroidal
anti-inflammatory drug-activated gene-1. Mol Pharmacol 68: 1782–1792.
31. Smits VA, Klompmaker R, Vallenius T, Rijksen G, Makela TP, et al. (2000) p21
inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage
checkpoint. J Biol Chem 275: 30638–30643.
32. Doonan F, Wallace DM, O’Driscoll C, Cotter TG (2009) Rosiglitazone acts as a
neuroprotectant in retinal cells via up-regulation of sestrin-1 and SOD-2.
J Neurochem 109: 631–643.
33. Michalovitz D, Halevy O, Oren M (1990) Conditional inhibition of
transformation and of cell proliferation by a temperature-sensitive mutant of
p53. Cell 62: 671–680.
34. Stewart N, Hicks GG, Paraskevas F, Mowat M (1995) Evidence for a second cell
cycle block at G2/M by p53. Oncogene 10: 109–115.
35. Vikhanskaya F, Erba E, D’Incalci M, Broggini M (1994) Introduction of wild-
type p53 in a human ovarian cancer cell line not expressing endogenous p53.
Nucleic Acids Res 22: 1012–1017.
36. Kim YH, Jung EM, Lee TJ, Kim SH, Choi YH, et al. (2008) Rosiglitazone
promotes tumor necrosis factor-related apoptosis-inducing ligand-induced
apoptosis by reactive oxygen species-mediated up-regulation of death receptor
5 and down-regulation of c-FLIP. Free Radic Biol Med 44: 1055–1068.
37. Chen F, Kim E, Wang CC, Harrison LE (2005) Ciglitazone-induced p27 gene
transcriptional activity is mediated through Sp1 and is negatively regulated by
the MAPK signaling pathway. Cell Signal 17: 1572–1577.
38. Inoue T, Kamiyama J, Sakai T (1999) Sp1 and NF-Y synergistically mediate the
effect of vitamin D(3) in the p27(Kip1) gene promoter that lacks vitamin D
response elements. J Biol Chem 274: 32309–32317.
39. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD (1999) Expression of
peroxisome proliferator-activated receptor gamma (PPARgamma) in human
transitional bladder cancer and its role in inducing cell death. Neoplasia 1:
330–339.
40. Bogazzi F, Ultimieri F, Raggi F, Russo D, Vanacore R, et al. (2004)
PPARgamma inhibits GH synthesis and secretion and increases apoptosis of
pituitary GH-secreting adenomas. Eur J Endocrinol 150: 863–875.
41. Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, et al. (2004) Tumor
necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus
Calmette-Guerin-induced antitumor activity. Cancer Res 64: 3386–3390.
42. Kamat AM, Lamm DL (2001) Immunotherapy for bladder cancer. Curr Urol
Rep 2: 62–69.
43. Schultze K, Bock B, Eckert A, Oevermann L, Ramacher D, et al. (2006)
Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-
regulation of FLIP and Survivin. Apoptosis 11: 1503–1512.
44. Senthivinayagam S, Mishra P, Paramasivam SK, Yallapragada S, Chatterjee M,
et al. (2009) Caspase-mediated cleavage of beta-catenin precedes drug-induced
apoptosis in resistant cancer cells. J Biol Chem 284: 13577–13588.
45. Lu M, Kwan T, Yu C, Chen F, Freedman B, et al. (2005) Peroxisome
proliferator-activated receptor gamma agonists promote TRAIL-induced
apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle
arrest. J Biol Chem 280: 6742–6751.
46. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y (2007) Association of cyclin D1
and E1 expression with disease progression and biomarkers in patients with
nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol 25:
468–475.
47. Ning S, Fuessel S, Kotzsch M, Kraemer K, Kappler M, et al. (2004) siRNA-
mediated down-regulation of survivin inhibits bladder cancer cell growth.
Int J Oncol 25: 1065–1071.
48. Ku JH, Seo SY, Kwak C, Kim HH (2010) Cytotoxicity and apoptosis by survivin
small interfering RNA in bladder cancer cells. BJU Int 106: 1812–1816.
49. O’Connor DS, Grossman D, Plescia J, Li F, Zhang H, et al. (2000) Regulation of
apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl
Acad Sci U S A 97: 13103–13107.
50. Kim DJ, Murray IA, Burns AM, Gonzalez FJ, Perdew GH, et al. (2005)
Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell
proliferation by down-regulation of kinase activity. J Biol Chem 280: 9519–9527.
Ciglitazone Induces Bladder Tumor Cells Apoptosis
PLoS ONE | www.plosone.org 12 December 2011 | Volume 6 | Issue 12 | e28354